Spring 2015 Commentary
Dear Valued Clients and Friends,
MARKET PERSPECTIVE: The first quarter of 2015 had a little something for everyone. We started the year with a sharp downdraft, followed by a consolidation in a wide range, culminating with a solid uptrend into new high ground led by renewed interest in the small cap sector as depicted in the chart featured below. The end result was that the S&500 was up 0.43%, the Russell 2000 Growth plus 6.45%, and the Rocket Capital Small Cap Composite up 5.25%. The slight underperformance in Rocket’s Small-Cap Composite again can be traced to the outsized cash bal-ance held in the portfolio early in the quarter, averaging 29%. We held this cash position due to a shortage of high quality chart patterns and a lack of the strong fundamentals that we require. The
TECHNICAL PERSPECTIVE: The technical outlook for the stock market remains positive after a very strong start to the year. However, after recently making new highs the indexes are struggling to hang on to their gains, evi-denced by the recent increase in volatility. It would not be at all unusual to experience a period of consolidation or modest correction here, although it most likely will be a pause that refreshes than the beginning of a meaningful move on the down side. Individual chart patterns remain healthy with the majority being in basing patterns or solid up trends. The exception to this is an increasing number of chart patterns that are up sharply and very overextended. This activity should be viewed with caution. In managing portfolios, we have taken advantage of these moves by trimming our positions in overextended winners. Looking at the sentiment numbers, we see that investors are not noticeably more bullish than they were at the beginning of the year, which is interesting. All things considered, when the dust settles, I believe the trend will remain up. Short term support on the Russell 2000 Growth Index (IWO) is at the 150 level and, if broken, the next level would be at the 144 area.
Continued On Back
SECTOR COMMENT: The sector leader board has again been dominated by stocks and sectors related to the healthcare industry as has been the case for quite some time. Recently, however, we have begun to see signs of top-ping action in the red hot bio-tech group as many of them are very overextended and experienced in blow off tops. This doesn’t suggest that the uptrend in bio-techs is over, just that the easy money has been made for now. Be selec-tive here. In other sectors, Information Technology, including both hardware and software, continue to be in solid up trends. The sectors to focus on are semi conductor manufacturing in hardware and network security in software. The Telecommunications infrastructure sector is also improving. In our opinion, we have seen the low oil and energy re-lated sectors but, because the group has been badly broken, we continue to avoid these sectors for now.
PORTFOLIO ADJUSTMENTS: In the 1st quarter we added 7 new companies to our portfolio that passed our tech-nical and fundamental screening criteria: Horizon Pharma Plc (HZNP), Silicon Motion Corp (SIMO), Lannett Compa-ny, Inc (LCI), Astronics Corporation (ATRO), Monotype Imaging Holdings (TYPE), Enphase Energy, Inc (ENPH), and Ellie Mae, Inc (ELLI). We sold MiMedix Group, Inc (MDXG), LifeLock, Inc (LOCK), and Acacia Research Corporation (ACTG) because they broke down technically, fundamentally or both. We trimmed two positions: Am-barella, Inc (AMBA) and Horizon Pharma Plc (HZNP) because they had grown to become too large a percentage of the portfolio.
HORIZON PHARMA PLC (HZNP $25.97) : Horizon Pharma PLC is a specialty biopharmaceutical company focused on improving pa-tients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The Compa-ny markets a portfolio of products in arthritis, inflammation and or-phan diseases. Horizon’s U.S. marketed products are ACTIMMUNE, DUEXIS®, PEN w/w, RAYOS® (prednisone) delayed-release tablets, and VIMOVO®. Horizon recently announced that they have entered a definitive agreement to acquire Hyperion Therapeutics. This acquisition is expected to increase the number of products from five to seven and will leverage Horizon’s orphan business and offer attractive revenue and operating efficiencies. The addition of Hype-rion, coupled with its existing products, should enable Horizon to grow their top and bottom line quite meaningfully for the foreseeable future.
While we remain confident that the trend is up, recent volatility suggests that now is not the time to throw caution to the wind. Bearing that in mind we will be extremely diligent in plotting our next course of action.
As always, if you have any questions, comments or concerns do not hesitate to call or email us at any time and will get back to you promptly. Your continued confidence in Rocket Capital Management is greatly appreciated and we look forward to a long and meaningful relationship.
President / Senior Portfolio Manager
The information concerning the stocks contained herein should not be construed as a recommendation to buy or sell them in your individual investment accounts. The opinions expressed are those solely of Rocket Capital Management, LLC and are subject to change. Accounts at Rocket Capital Management, LLC may hold long or short positions of the stocks mentioned in this publication. In addition, employees, members, or other affiliates of Rocket Capital Management, LLC may hold long or short positions of the stocks mentioned in this publication, which may be inconsistent with the information contained herein. Rocket Capital Managed Accounts performance is net of management fees and wrap fees. Sources: www.horizonpharma.com. *Closing market price on 3/31/2015.